Reference health
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
00146-3/badge.svg){kind=icon}
21/21 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
9 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 21 checked references that resolve
resolves10.1016/S1473-3099(21)00566-1
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
resolves10.1056/NEJMoa2114583
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
resolves10.1038/s41591-021-01583-4
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
resolves10.1038/s41591-021-01446-y
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
resolves10.1056/NEJMoa2114114
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
resolves10.1126/science.abm0620
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
resolves10.1126/scitranslmed.abj0847
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
resolves10.1016/S0140-6736(21)02249-2
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
resolves10.1016/S0140-6736(21)02717-3
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
resolves10.1016/S0140-6736(21)01694-9
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
resolves10.1038/s41591-020-0916-2
Real-time tracking of self-reported symptoms to predict potential COVID-19
resolves10.1016/S1473-3099(21)00224-3
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
resolves10.1016/S2352-4642(21)00198-X
Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2
resolves10.1038/s41591-020-01194-5
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
resolves10.1016/S0140-6736(21)02183-8
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
resolves10.1016/S2468-2667(20)30269-3
Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study
The 9 references without a DOI — listed, not checked
no DOI — not checkedEffectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
no DOI — not checkedAssociations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with COVID-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study
no DOI — not checkedEffectiveness of the WHO-authorized COVID-19 vaccines: a rapid review of global reports till 30 June 2021
no DOI — not checkedEffectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against COVID-19 related symptoms in England: test negative case-control study
no DOI — not checkedCOVID-19: booster vaccine gives “significant increased protection” in over 50s
no DOI — not checkedA country-by-country guide to coronavirus vaccine booster plans
no DOI — not checked10.1016/S1473-3099(22)00146-3_bib20
no DOI — not checkedFDA authorizes coronavirus booster shots for all adults
no DOI — not checkedCOVID-19: booster doses to be offered to 30 million people in UK
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s1473-3099(22)00146-3"><img src="https://citestamp.com/citestamped/10.1016/s1473-3099(22)00146-3/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[00146-3/badge.svg)](https://citestamp.com/citestamped/10.1016/s1473-3099(22)00146-3)